Abstract
Energy homeostasis in mammalians is a teleological process regulated by the interplay between caloric intake and energy expenditure. Incretins are a significant component of the complex homeostatic network regulating the metabolic state in humans. This narrative review will focus on the basic concepts regarding incretins physiology and their regulatory feedback mechanisms affecting energy homeostasis. In this context, glucagon-like peptide 1 (GLP-1) promotes satiety and weight loss through centrally and peripherally mediated pathways. On the other hand, gastric inhibitory peptide (GIP) is implicated in energy storage by its actions on adipose tissue. Understanding this biological model requires a holistic approach, since it is dually manifested by promoting weight reduction, in the case of GLP-1, or favoring lipid accumulation, in the case of GIP. The complete spectrum of incretin actions related to energy homeostasis is yet to be fully elucidated. Currently, new drugs based on incretin physiology are available for treatment of type 2 diabetes mellitus, whereas the implication of similar drugs in the treatment of obesity is under investigation. These agents exert several beneficial effects that minimize cardiovascular risk.
Keywords: Energy homeostasis, glucagon-like peptide 1 (GLP-1), gastric inhibitory peptide (GIP), incretins, obesity, type 2 diabetes mellitus
Current Vascular Pharmacology
Title:The Effects of Incretins on Energy Homeostasis: Physiology and Implications for the Treatment of Type 2 Diabetes Mellitus and Obesity
Volume: 10 Issue: 6
Author(s): Spyridon Karras, Dimitrios G. Goulis, Gesthimani Mintziori, Niki Katsiki and Themistoklis Tzotzas
Affiliation:
Keywords: Energy homeostasis, glucagon-like peptide 1 (GLP-1), gastric inhibitory peptide (GIP), incretins, obesity, type 2 diabetes mellitus
Abstract: Energy homeostasis in mammalians is a teleological process regulated by the interplay between caloric intake and energy expenditure. Incretins are a significant component of the complex homeostatic network regulating the metabolic state in humans. This narrative review will focus on the basic concepts regarding incretins physiology and their regulatory feedback mechanisms affecting energy homeostasis. In this context, glucagon-like peptide 1 (GLP-1) promotes satiety and weight loss through centrally and peripherally mediated pathways. On the other hand, gastric inhibitory peptide (GIP) is implicated in energy storage by its actions on adipose tissue. Understanding this biological model requires a holistic approach, since it is dually manifested by promoting weight reduction, in the case of GLP-1, or favoring lipid accumulation, in the case of GIP. The complete spectrum of incretin actions related to energy homeostasis is yet to be fully elucidated. Currently, new drugs based on incretin physiology are available for treatment of type 2 diabetes mellitus, whereas the implication of similar drugs in the treatment of obesity is under investigation. These agents exert several beneficial effects that minimize cardiovascular risk.
Export Options
About this article
Cite this article as:
Karras Spyridon, G. Goulis Dimitrios, Mintziori Gesthimani, Katsiki Niki and Tzotzas Themistoklis, The Effects of Incretins on Energy Homeostasis: Physiology and Implications for the Treatment of Type 2 Diabetes Mellitus and Obesity, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520909
DOI https://dx.doi.org/10.2174/157016112803520909 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design An Association between MicroRNA-21 Expression and Vitamin D Deficiency in Coronary Artery Disease
MicroRNA Retracted: Tocotrienols and its Role in Cardiovascular Health- a Lead for Drug Design
Current Pharmaceutical Design Breast-Milk Characteristics Protecting Against Allergy
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapies Targeting Inflammation After Stent Implantation
Current Vascular Pharmacology Ghrelin and the Brain-gut Axis as a Pharmacological Target for Appetite Control
Current Pharmaceutical Design Arrhythmias and Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design Relationship between Fatty Acid Habitual Intake and Early Inflammation Biomarkers in Individuals with and without Type 2 Diabetes in Mexico
Endocrine, Metabolic & Immune Disorders - Drug Targets Structure-based Design on Anticancer Drug Discovery
Current Topics in Medicinal Chemistry Niacin Status, NAD Distribution and ADP-Ribose Metabolism
Current Pharmaceutical Design Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Diabetic Retinopathy: Current and New Treatment Options
Current Diabetes Reviews Macronutrient Intake and Distribution in the Etiology, Prevention and Treatment of Osteosarcopenic Obesity
Current Aging Science Metabolic Syndrome, its Pathophysiology and the Role of Melatonin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies
Current Vascular Pharmacology Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design Pharmacology and Chemistry of Diabetes mellitus and Antidiabetic Drugs: A Critical Review
Current Medicinal Chemistry Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design Novel Glitazones with Diverse Peroxisome Proliferator Activated Receptor Modulatory Potential
Current Bioactive Compounds